Publications

391 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Appendix to guideline for cost-effectiveness models in R - packages and versions

Appendix to guideline for cost-effectiveness models in R - packages and versions.

Publication | 15-12-2022
Guideline for building cost-effectiveness models in R

Guideline for building cost-effectiveness models in R.

Publication | 15-12-2022
GVS advice to include house dust mite extract 300 IR HDM (Actair®)

The National Health Care Institute has completed its assessment whether house dust mite extract 300 IR HDM (Actair®) can be ...

Report | 10-11-2022
Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)

The National Health Care Insititue has completed its assessment whether pralsetinib (Gavreto®) can be included in the basic ...

Report | 10-11-2022
GVS advice on natalizumab SC (Tysabri®) for adult patients with highly active RRMS

The National Health Care Institute has completed its assessment whether natalizumab SC (Tysabri®) can be included in the Medicine ...

Report | 25-10-2022
Package advice on ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsing and refractory multiple myeloma (RRMM)

The National Health Care Institute advises the Minister not to include ciltacabtagene autoleucel (Carvykti®) for the treatment of ...

Report | 20-10-2022
GVS advice to include the relugolix in combination with oestradiol and norethisteronacetate (Ryeqo®) combination

The National Health Care Institute has completed its assessment whether relugolix in combination with oestradiol and ...

Report | 19-10-2022
Evaluation and reassessment of further conditions for fampridine (Fampyra®)

The National Health Care Institute advises the Minister that the fampridine (Fampyra®) conditions be revised and that the annual ...

Report | 17-10-2022
Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...

Report | 27-09-2022
GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection

The National Health Care Institute advises the Minister to include lenacapavir (Sunlenca®) on List 1B of the Medicine ...

Report | 22-09-2022

Publications

391 publications

Appendix to guideline for cost-effectiveness models in R - packages and versions

Guideline for building cost-effectiveness models in R

GVS advice to include house dust mite extract 300 IR HDM (Actair®)

Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)

GVS advice on natalizumab SC (Tysabri®) for adult patients with highly active RRMS

Package advice on ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsing and refractory multiple myeloma (RRMM)

GVS advice to include the relugolix in combination with oestradiol and norethisteronacetate (Ryeqo®) combination

Evaluation and reassessment of further conditions for fampridine (Fampyra®)

Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection

Go to